IL-6-induced STAT3 or STAT5 activation is associated with the acquired resistance to PI3K inhibitors in T- and B-cell lymphoma cell lines, and co-targeting JAK/STAT3 and PI3K signaling resensitizes the lymphoma cell lines to a PI3K inhibitor [145]. The gene discussed is STAT3; the disease is lymphoma.